Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

ClinicalTrials.gov ID: NCT00125827

Public ClinicalTrials.gov record NCT00125827. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Dose Escalation and Pharmacokinetic Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

Study identification

NCT ID: NCT00125827
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Genzyme, a Sanofi Company; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Solid Tumors

Interventions

clofarabine (oral formulation) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2003
Primary completion: Sep 30, 2004
Completion: Jan 31, 2006
Last update posted: Mar 18, 2014

2003 – 2006

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 3

Facility	City	State	ZIP	Site status
Mary Crowley Medical Research Center	Dallas	Texas	75246	—
Tyler Cancer Institute	Tyler	Texas	75702	—
Cancer Care Northwest	Spokane	Washington	99218	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00125827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 18, 2014 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00125827 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →